# almirall.com

> AI-optimized mirror of almirall.com containing 50 pages totalling 29,319 words of clean markdown content, structured data, and semantic HTML. Original source: https://almirall.com. Last updated: 2026-09-07T02:42:47.948Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Almirall | Pharmaceutical Company in Medical Dermatology](/content/site-root.html): Almirall is a global pharmaceutical company dedicated to medical dermatology, collaborating with leading scientists, healthcare professionals and patients. (360 words)

## Articles & Blog Posts

- [Pipeline | Almirall](/content/innovation/pipeline/index.html): In the Pipeline area of Almirall’s Innovation section, discover our late-stage developments focused on innovation and science to unlock mid-term growth. (223 words)
- [Events, congresses and meetings | Almirall](/content/news-media/event-calendar/index.html): In the Event Calendar area, find upcoming Almirall events. (578 words)
- [CNMV Communications | Almirall](/content/investors/cnmv-communications/index.html): In the CNMV Communications section of Almirall’s Investors area, you will find insider information disclosed to the CNMV and accessible on its website. (206 words)
- [Hidradenitis suppurativa: What It Is | Almirall](/content/dermatology/hidradenitis-suppurativa/index.html): Hidradenitis suppurativa, also known as acne inversa, is a chronic skin disease characterised by painful nodules or abscesses forming beneath the skin. (937 words)
- [Vitiligo: What It Is | Almirall](/content/dermatology/vitiligo/index.html): Vitiligo is a non-contagious chronic skin condition and is associated with a loss of pigmentation due to the progressive destruction of melanocytes, the skin cells that produce melanin and are responsible for skin colour. (1,164 words)
- [Rare skin diseases | Almirall](/content/dermatology/rare-skin-diseases/index.html): Rare skin diseases are mostly genetic, chronic and degenerative conditions that affect few people and often lack approved or specific treatments. (434 words)
- [Psoriasis: What It Is | Almirall](/content/dermatology/psoriasis/index.html): Psoriasis is a chronic inflammatory skin condition in dermatology characterised by red, scaly plaques that may affect the skin, nails and joints. (1,188 words)
- [Duaklir® will be available in the United States from 21st October | Almirall](/content/news-media/newsroom/duaklirr-will-be-available-united-states-21st-october.html): Circassia announces Duaklir® US launch at American College of Chest Physicians’ CHEST Annual Meeting 2019 Almirall receives a milestone of $100 MM coming from AstraZeneca agreement when the first commercial sale takes place In 2014 Almirall entered into an agreement with AstraZeneca to transfer the rights for the development and commercialization of the Almirall respiratory franchise (804 words)
- [Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases | Almirall](/content/news-media/newsroom/almirall-and-eloxx-pharmaceuticals-enter-exclusive-agreement-license-zkn-013.html): Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations. ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP). (1,280 words)
- [Acne: What It Is | Almirall](/content/dermatology/acne/index.html): Acne is one of the most common skin disorders in dermatology, a chronic inflammatory disease that includes hormonal acne with papules, pustules and nodules. (1,091 words)
- [Actinic keratosis: What It Is | Almirall](/content/dermatology/actinic-keratosis/index.html): Actinic keratosis, or solar keratosis, is a medical condition that appears in sun-damaged skin. (991 words)
- [Career Privacy Notice | Almirall](/content/career-privacy-notice/index.html): We are a pharmaceutical company committed to research and development of medicines for patients around the world. Find out. Feel the science! (1,305 words)
- [Onychomycosis: What It Is | Almirall](/content/dermatology/onychomycosis/index.html): Onychomycosis is the most common nail infection disorder in dermatology, affecting toenails and fingernails with white, yellow or black spots. (854 words)
- [Commitment to Patients | Almirall](/content/patients/index.html): Patients at the heart of what we do: Almirall’s patient centric dermatology, real stories, and resources for psychological well-being. (726 words)
- [Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for atopic dermatitis | Almirall](/content/news-media/newsroom/almirall-exercises-its-option-dermira-license-rights-lebrikizumab-europe-atopic.html): nan (1,202 words)
- [Corporate Responsibility & Compliance | Almirall](/content/investors/compliance/index.html): Corporate responsibility and compliance guide how we operate at Almirall, showing our commitment to ethical conduct, sustainability and patient care. (581 words)
- [Financial information materials | Almirall](/content/investors/financial-data/information-materials/index.html): In the Financial Information Materials section of Almirall’s Investors area, you will find documents summarizing the company’s financial performance. (394 words)
- [Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody | Almirall](/content/news-media/newsroom/ichnos-sciences-and-almirall-enter-licensing-agreement-first-class-il-1rap.html): Almirall is Granted Exclusive Global Rights to Develop and Commercialize ISB 880 for Use in Autoimmune Diseases (745 words)
- [Board Comissions | Almirall](/content/investors/corporate-governance/board-comissions/index.html): In the Board Commissions area of Almirall’s Investors section, learn about the committees supporting the Board in governance and decision-making. (146 words)
- [Atopic dermatitis: What It Is | Almirall](/content/dermatology/atopic-dermatitis/index.html): Atopic dermatitis (AD), or atopic eczema, is a non-contagious chronic inflammatory skin disease, characterised by redness, itching and dryness. (887 words)
- [Keratinocyte cancer: What It Is | Almirall](/content/dermatology/keratinocyte-cancer/index.html): Keratinocyte cancer (KC) is the most common type of cancer in dermatology, caused by abnormal growth of skin cells due to excessive sun exposure. (801 words)
- [Global drug safety privacy policy | Almirall](/content/drug-safety/index.html): At Almirall, our commitment to the safety of our medicines, medical devices, cosmetics and healthcare products starts from the Research and Development (R&D) department and is maintained throughout the life of the product. (1,010 words)
- [Almirall licenses Aclidinium to Daewoong in Korea | Almirall](/content/news-media/newsroom/almirall-licenses-aclidinium-daewoong-korea/index.html): nan (874 words)
- [Analyst Coverage | Almirall](/content/investors/stock-information/analyst-coverage/index.html): In the Analyst Coverage section of Almirall’s Stock Information area for Investors, you will find a list of financial analysts following Almirall, S.A. (193 words)
- [Corporate Actions & Financing | Almirall](/content/investors/stock-information/actions-financing/index.html): In the Corporate Actions and Financing section of Almirall’s Stock Information for Investors, you will find information on financial operations and events. (226 words)
- [Financial and Governance Reports | Almirall](/content/investors/reports/index.html): In the Reports area of Almirall’s Investors section, access the company’s yearly financial, governance and directors’ reports. (162 words)
- [Almirall and Microsoft announce partnership for digital transformation to enable the development of novel treatments for skin diseases | Almirall](/content/news-media/newsroom/almirall-and-microsoft-announce-partnership-digital-transformation-enable.html): The three-year collaboration is aimed at accelerating digitalization and technology innovation to advance medical dermatology and develop next-generation personalized drugs The partners will apply generative artificial intelligence (genAI) and advanced analytics technologies to identify innovation opportunities in medical dermatology for Almirall's pipeline portfolio (624 words)
- [Corporate Governance | Almirall](/content/investors/corporate-governance/index.html): In the Corporate Governance section of Almirall’s Investors area, you will find information on our governance principles, policies and structure. (298 words)
- [Share Capital & Ownership | Almirall](/content/investors/stock-information/share-capital/index.html): In the Share Capital and Ownership section of Almirall’s Stock Information, you will find details on our share structure, voting rights and capital. (298 words)
- [Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab | Almirall](/content/news-media/newsroom/almirall-and-dermira-enter-option-and-license-agreement-european-rights.html): nan (591 words)
- [Alopecia areata: What It Is | Almirall](/content/dermatology/alopecia-areata/index.html): Alopecia areata is a common autoimmune disease in dermatology that causes sudden hair loss in well-defined patches on the scalp and other body areas. (775 words)
- [Sustainability | Almirall](/content/company/sustainability/index.html): Almirall’s 2030 Sustainability Strategy, Act4Impact, drives positive change for patients, people, partners and the planet through science and ethics. (766 words)
- [Stock Information | Almirall](/content/investors/stock-information/index.html): Discover Almirall’s Stock Information section for investors, featuring data on share performance, capital, ownership, financing and analyst coverage. (245 words)
- [Pharmaceutical Innovation | Almirall](/content/innovation/index.html): In the Innovation area, explore Almirall's pipeline, clinical trials, R&D Collaborations, partnerships and papers driving future growth. (574 words)
- [Investors | Almirall](/content/investors/index.html): Discover Almirall’s investor section with financial data, share information, governance details and reports for shareholders and analysts. (110 words)
- [Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole | Almirall](/content/news-media/newsroom/almirall-and-kaken-pharmaceutical-enter-license-and-distribution-agreement.html): Efinaconazole is a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis Almirall acquires exclusive rights for the development and commercialization of this topical antifungal in Europe (578 words)
- [Shareholders Annual General Meeting | Almirall](/content/investors/corporate-governance/annual-meeting/index.html): In the Shareholders Annual General Meeting area of Almirall’s Investors section, access regulations, agenda, proposals, and voting tools for shareholders. (105 words)
- [Almirall and Paratek enter into a License Agreement for Seysara® in China | Almirall](/content/news-media/newsroom/almirall-and-paratek-enter-license-agreement-seysarar-china.html): Almirall has been commercializing sarecycline (acne) in the US since January 2019. The drug was approved by the FDA in October 2018, following the acquisition of the US medical dermatology portfolio from Allergan. Seysara® to become the first dermatology product of Almirall’s strategic portfolio in China. Seysara® Phase 3 study expected to start in 2020. Submission to regulatory body in 2023. (564 words)
- [Newsroom | Almirall](/content/news-media/newsroom/index.html): In the Newsroom area, explore the latest updates, press releases, and news from Almirall. (396 words)
- [Financial Results Q1 2026 | Almirall](/content/news-media/newsroom/financial-results-q1-2026/index.html): Today, we shared our financial results for the first quarter of 2026, continuing our positive trajectory and delivering performance in line with expectations and our long-term growth strategy. (307 words)
- [Almirall announces the initiation of a phase I study of anti-IL-1RAP first-in-class monoclonal antibody for autoimmune dermatological diseases | Almirall](/content/news-media/newsroom/almirall-announces-initiation-phase-i-study-anti-il-1rap-first-class-monoclonal.html): The phase I study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ALM27134* ALM27134 has the potential to treat underserved patients with a variety of autoimmune dermatological diseases (420 words)
- [Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a first-in-class agent in dermatology | Almirall](/content/news-media/newsroom/almirall-licenses-anti-il-21-monoclonal-antibody-novo-nordisk-develop-it-first.html): Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated diseases (382 words)
- [Almirall signs a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound | Almirall](/content/news-media/newsroom/almirall-signs-pan-european-licensing-agreement-ironwood-linaclotide-novel.html): nan (747 words)
- [Almirall meets 2025 guidance, delivering 12.4% net sales growth and continued pipeline progress | Almirall](/content/news-media/newsroom/almirall-meets-2025-guidance-delivering-124-net-sales-growth-and-continued.html): Our full-year financial results confirmed that we sustained a solid growth trajectory in 2025, meeting our full‑year guidance and underscoring our leadership in medical dermatology. We have delivered solid financial results, continued investment in innovation, and proved the strength of our dermatology‑focused strategy in Europe. (232 words)
- [Healthcare professionals | Almirall](/content/healthcare-professional/index.html): Our close partnership with patients and dermatologists makes us a trusted and reliable partner to them. (21 words)
- [Almirall and GW announce European development and marketing agreement for Sativex® | Almirall](/content/news-media/newsroom/almirall-and-gw-announce-european-development-and-marketing-agreement-sativexr.html): nan (733 words)
- [Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc | Almirall](/content/news-media/newsroom/almirall-and-simcere-enter-licensing-agreement-il-2-mu-fc.html): Simcere will receive a $15 million upfront payment and up to US$492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon future global sales Under the agreement, Almirall will be granted an exclusive right to develop and commercialise SIM0278 for all indications outside of the Greater China region SIM0278 is an interleukin 2 mutant fusion protein (IL-2 mu-Fc) that activates T regulatory cells. As an IND ready subcutaneous injection, it can be developed to potentially treat various autoimmune diseases (734 words)
- [Dermatology and Skin Conditions | Almirall](/content/dermatology/index.html): Discover key skin conditions and Almirall’s dermatology expertise in science, innovation and care to improve patients’ skin health. (362 words)
- [Agreements between significant shareholders | Almirall](/content/investors/corporate-governance/agreements/index.html): In the Agreements between Significant Shareholders area of Almirall’s Investors section, you can download the latest agreements between major shareholders. (95 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives
- [AgentSite Network](https://agentsite.network/network.html): Public index of AgentSites and their machine-readable resources